CN1761665A - 抗肿瘤效果增强剂和抗肿瘤剂 - Google Patents

抗肿瘤效果增强剂和抗肿瘤剂 Download PDF

Info

Publication number
CN1761665A
CN1761665A CNA2004800069779A CN200480006977A CN1761665A CN 1761665 A CN1761665 A CN 1761665A CN A2004800069779 A CNA2004800069779 A CN A2004800069779A CN 200480006977 A CN200480006977 A CN 200480006977A CN 1761665 A CN1761665 A CN 1761665A
Authority
CN
China
Prior art keywords
tegafur
antitumor
potassium
oxonate
enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800069779A
Other languages
English (en)
Chinese (zh)
Inventor
内田淳二
首藤光洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of CN1761665A publication Critical patent/CN1761665A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CNA2004800069779A 2003-03-14 2004-03-11 抗肿瘤效果增强剂和抗肿瘤剂 Pending CN1761665A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003070097 2003-03-14
JP070097/2003 2003-03-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008101445581A Division CN101357134A (zh) 2003-03-14 2004-03-11 抗肿瘤效果增强剂和抗肿瘤剂

Publications (1)

Publication Number Publication Date
CN1761665A true CN1761665A (zh) 2006-04-19

Family

ID=32984641

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004800069779A Pending CN1761665A (zh) 2003-03-14 2004-03-11 抗肿瘤效果增强剂和抗肿瘤剂
CNA2008101445581A Pending CN101357134A (zh) 2003-03-14 2004-03-11 抗肿瘤效果增强剂和抗肿瘤剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008101445581A Pending CN101357134A (zh) 2003-03-14 2004-03-11 抗肿瘤效果增强剂和抗肿瘤剂

Country Status (21)

Country Link
US (2) US9611227B2 (https=)
EP (1) EP1604991B1 (https=)
JP (1) JP4610481B2 (https=)
KR (1) KR100812693B1 (https=)
CN (2) CN1761665A (https=)
AT (1) ATE408408T1 (https=)
AU (1) AU2004220205B2 (https=)
BR (1) BRPI0408372A (https=)
CA (1) CA2518195C (https=)
CY (1) CY1108395T1 (https=)
DE (1) DE602004016636D1 (https=)
DK (1) DK1604991T3 (https=)
ES (1) ES2312978T3 (https=)
MX (1) MXPA05009781A (https=)
NZ (1) NZ542150A (https=)
PL (1) PL1604991T3 (https=)
PT (1) PT1604991E (https=)
RU (1) RU2334517C2 (https=)
SI (1) SI1604991T1 (https=)
TW (1) TW200503720A (https=)
WO (1) WO2004081012A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102309491A (zh) * 2010-07-02 2012-01-11 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155600B (zh) * 2005-04-01 2011-05-04 大鹏药品工业株式会社 放射线治疗增强剂
KR101135789B1 (ko) * 2005-04-01 2012-04-16 다이호야쿠힌고교 가부시키가이샤 피리딘 유도체를 유효성분으로 하는 방사선 치료 증강제
WO2007043531A1 (ja) * 2005-10-07 2007-04-19 Celestar Lexico-Sciences, Inc. 抗腫瘍剤及び放射線併用療法感受性診断用遺伝子マーカー並びにその利用
WO2009139085A1 (ja) * 2008-05-12 2009-11-19 静岡県 抗腫瘍剤、キット及び癌治療方法
JP5553522B2 (ja) * 2009-03-31 2014-07-16 大鵬薬品工業株式会社 経口投与用医薬組成物
TW201043237A (en) 2009-04-22 2010-12-16 Taiho Pharmaceutical Co Ltd Method for predicting a therapeutic effect of the chemotherapy for renal cell cancer
MX353289B (es) * 2011-05-25 2018-01-05 Taiho Pharmaceutical Co Ltd Tableta revestida en seco que contiene tegafur, gimeracil y oteracil potasico.
RU2657783C2 (ru) * 2013-09-30 2018-06-15 Тайхо Фармасьютикал Ко., Лтд. Комбинированная терапия с использованием азабициклосоединения для ракового заболевания
CN106581001B (zh) * 2016-11-03 2018-12-21 江苏恒瑞医药股份有限公司 一种替吉奥组合物的制备方法
KR102258514B1 (ko) 2019-09-23 2021-05-31 연세대학교 산학협력단 신규한 다층형 좌약 제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL194430C (nl) 1989-01-05 2002-04-04 Otsuka Pharma Co Ltd Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
JP2557303B2 (ja) * 1990-09-07 1996-11-27 大鵬薬品工業株式会社 抗腫瘍効果増強剤及び抗腫瘍剤
EP0543015B1 (en) * 1991-05-27 1998-11-11 Taiho Pharmaceutical Co., Ltd. Composition, method and kit for potentiating antitumor activity and for curing tumor
CH683262A5 (it) * 1992-01-22 1994-02-15 Applied Pharma Res Procedimento per la separazione dei diastereomeri del sale di calcio dell'acido (6(R,S)-N-formiltetraidrofolico).
WO2001066102A2 (en) * 2000-03-08 2001-09-13 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
MXPA03007989A (es) 2001-03-06 2003-12-04 Bristol Myers Squibb Co Metodo y forma de dosificacion para tratamiento de tumores por administracion de tegafur, uracil, acido folinico, paclitaxel y carboplatin.
DE60235088D1 (de) * 2001-07-05 2010-03-04 Taiho Pharmaceutical Co Ltd Dna-arrays zur messung der empfindlichkeit gegenüber einem antikrebsmittel

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102309491A (zh) * 2010-07-02 2012-01-11 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
CN106692173A (zh) * 2015-11-18 2017-05-24 北京诺普德医药科技有限公司 一种抗肿瘤复方组合物及其应用

Also Published As

Publication number Publication date
US20060116345A1 (en) 2006-06-01
US20170157131A1 (en) 2017-06-08
JP4610481B2 (ja) 2011-01-12
KR100812693B1 (ko) 2008-03-13
WO2004081012A1 (ja) 2004-09-23
TW200503720A (en) 2005-02-01
CN101357134A (zh) 2009-02-04
CA2518195C (en) 2009-07-07
KR20050106119A (ko) 2005-11-08
RU2334517C2 (ru) 2008-09-27
SI1604991T1 (sl) 2009-02-28
JPWO2004081012A1 (ja) 2006-06-08
DK1604991T3 (da) 2009-01-05
PT1604991E (pt) 2008-10-27
US9814724B2 (en) 2017-11-14
AU2004220205B2 (en) 2010-06-17
PL1604991T3 (pl) 2009-02-27
EP1604991A1 (en) 2005-12-14
NZ542150A (en) 2009-09-25
BRPI0408372A (pt) 2006-03-21
ATE408408T1 (de) 2008-10-15
EP1604991B1 (en) 2008-09-17
EP1604991A4 (en) 2006-05-03
MXPA05009781A (es) 2005-10-26
CY1108395T1 (el) 2014-02-12
US9611227B2 (en) 2017-04-04
CA2518195A1 (en) 2004-09-23
AU2004220205A1 (en) 2004-09-23
DE602004016636D1 (de) 2008-10-30
TWI295173B (https=) 2008-04-01
ES2312978T3 (es) 2009-03-01
RU2005131839A (ru) 2006-02-10

Similar Documents

Publication Publication Date Title
CN1144587C (zh) 副作用减轻剂
CN1196484C (zh) 联合用作抗癌剂的药物组合物
CN1155600C (zh) 2,3-二芳基吡唑并[1,5-b]哒嗪衍生物,其制备方法和用作环氧酶2抑制剂
US9814724B2 (en) Antitumor effect potentiator and antitumor agent
CN1679559A (zh) 癌症的治疗
CN1527701A (zh) 在口腔中迅速崩解的片剂
CN101065127A (zh) 包含埃博霉素和蛋白酪氨酸激酶抑制剂的组合产品及其药物用途
CN1723021A (zh) 稳定的口服固体药物组合物
CN1301996C (zh) 喜树碱和不饱和脂肪酸的新的抗癌共轭体
CN101065114A (zh) 6－巯基嘌呤的改进制剂
CN1265793C (zh) 左西替利嗪伪麻黄碱复方口服制剂及制备方法
HK1090032A (en) Antitumor effect potentiator and antitumor agent
CN1589143A (zh) 癌症治疗的方法
CN1764453A (zh) 腹泻为主大肠激惹综合征的治疗制剂
CN1551778A (zh) 用于糖尿病神经病变的药物组合物
JP2020535112A (ja) Ｍｉｄｈ１阻害剤とｄｎａ低メチル化剤（ｈｍａ）との組合せ
RU2519199C2 (ru) Противоопухолевый агент, набор и способ лечения рака
CN1652844A (zh) 用于癌症治疗的cdk抑制剂和5－fu的联合
CN103054871A (zh) 抗肿瘤效果增强剂、抗肿瘤剂和癌治疗方法
CN1732919A (zh) 双环醇在制备预防和/或治疗急性酒精中毒和急慢性酒精性肝损伤药物中的应用
CN1374864A (zh) 癌的预防剂和治疗剂
TW202408499A (zh) 降低血中肌肉生長抑制素之藥劑
WO2026086880A1 (zh) Egfr抑制剂的药物组合与应用
HK1127546A (en) Antitumor effect potentiator and antitumor agent
CN1946396A (zh) 用于预防和/或治疗缺血性循环器官疾病的药剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1090032

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20060419

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1090032

Country of ref document: HK